Ken Griffin Next Cure, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Next Cure, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,400 shares of NXTC stock, worth $2,016. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,400
Previous 245,476
99.43%
Holding current value
$2,016
Previous $547,000
99.63%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding NXTC
# of Institutions
50Shares Held
16MCall Options Held
1.4KPut Options Held
0-
Sofinnova Investments, Inc. Menlo Park, CA2.67MShares$3.85 Million0.24% of portfolio
-
Logos Global Management LP San Francisco, CA2.5MShares$3.6 Million0.37% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.69MShares$2.43 Million0.37% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.14MShares$1.64 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA987KShares$1.42 Million0.0% of portfolio
About NextCure, Inc.
- Ticker NXTC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,748,800
- Market Cap $40M
- Description
- NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...